<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p183" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_183{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_183{left:306px;bottom:30px;}
#t3_183{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_183{left:346px;bottom:30px;}
#t5_183{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_183{left:517px;bottom:30px;}
#t7_183{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_183{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_183{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_183{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_183{left:35px;bottom:777px;letter-spacing:0.06px;word-spacing:0.12px;}
#tc_183{left:188px;bottom:785px;letter-spacing:-0.01px;}
#td_183{left:211px;bottom:777px;letter-spacing:0.02px;word-spacing:0.34px;}
#te_183{left:35px;bottom:754px;letter-spacing:0.07px;word-spacing:0.12px;}
#tf_183{left:35px;bottom:731px;letter-spacing:0.19px;}
#tg_183{left:35px;bottom:707px;letter-spacing:0.04px;word-spacing:0.28px;}
#th_183{left:35px;bottom:684px;letter-spacing:0.03px;word-spacing:0.28px;}
#ti_183{left:35px;bottom:661px;letter-spacing:0.1px;word-spacing:0.09px;}
#tj_183{left:35px;bottom:638px;letter-spacing:0.07px;word-spacing:0.12px;}
#tk_183{left:35px;bottom:614px;letter-spacing:0.12px;word-spacing:0.07px;}
#tl_183{left:35px;bottom:591px;letter-spacing:0.11px;word-spacing:0.08px;}
#tm_183{left:35px;bottom:568px;letter-spacing:0.16px;word-spacing:0.02px;}
#tn_183{left:35px;bottom:545px;letter-spacing:0.19px;word-spacing:0.11px;}
#to_183{left:35px;bottom:522px;letter-spacing:0.06px;word-spacing:0.43px;}
#tp_183{left:35px;bottom:498px;letter-spacing:0.13px;word-spacing:0.06px;}
#tq_183{left:35px;bottom:475px;letter-spacing:0.11px;word-spacing:0.08px;}
#tr_183{left:35px;bottom:452px;letter-spacing:0.12px;word-spacing:0.08px;}
#ts_183{left:35px;bottom:430px;letter-spacing:0.05px;word-spacing:-0.07px;}
#tt_183{left:352px;bottom:437px;letter-spacing:-0.01px;}
#tu_183{left:375px;bottom:430px;letter-spacing:0.1px;word-spacing:0.7px;}
#tv_183{left:35px;bottom:407px;letter-spacing:0.19px;word-spacing:0.12px;}
#tw_183{left:35px;bottom:383px;letter-spacing:0.14px;word-spacing:0.04px;}
#tx_183{left:35px;bottom:360px;letter-spacing:0.11px;word-spacing:0.07px;}
#ty_183{left:35px;bottom:337px;letter-spacing:-0.03px;word-spacing:0.92px;}
#tz_183{left:35px;bottom:314px;letter-spacing:0.03px;word-spacing:0.28px;}
#t10_183{left:549px;bottom:321px;letter-spacing:0.1px;}
#t11_183{left:35px;bottom:291px;letter-spacing:0.08px;word-spacing:0.11px;}
#t12_183{left:35px;bottom:267px;letter-spacing:0.02px;word-spacing:0.57px;}
#t13_183{left:35px;bottom:244px;letter-spacing:0.09px;word-spacing:0.09px;}
#t14_183{left:35px;bottom:221px;letter-spacing:0.05px;word-spacing:0.13px;}
#t15_183{left:35px;bottom:181px;letter-spacing:0.04px;word-spacing:0.33px;}
#t16_183{left:35px;bottom:157px;letter-spacing:0.13px;word-spacing:0.06px;}
#t17_183{left:35px;bottom:134px;letter-spacing:0.03px;word-spacing:0.31px;}
#t18_183{left:35px;bottom:111px;letter-spacing:0.05px;word-spacing:0.14px;}
#t19_183{left:35px;bottom:88px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1a_183{left:570px;bottom:88px;}
#t1b_183{left:35px;bottom:64px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t1c_183{left:81px;bottom:72px;letter-spacing:-0.01px;}
#t1d_183{left:104px;bottom:64px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1e_183{left:618px;bottom:777px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1f_183{left:618px;bottom:754px;letter-spacing:0.09px;word-spacing:0.22px;}
#t1g_183{left:618px;bottom:731px;letter-spacing:0.14px;word-spacing:0.25px;}
#t1h_183{left:618px;bottom:707px;letter-spacing:0.04px;word-spacing:0.25px;}
#t1i_183{left:618px;bottom:684px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1j_183{left:618px;bottom:661px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1k_183{left:618px;bottom:638px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1l_183{left:618px;bottom:614px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1m_183{left:618px;bottom:591px;letter-spacing:0.07px;word-spacing:0.24px;}
#t1n_183{left:618px;bottom:568px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1o_183{left:1096px;bottom:568px;}
#t1p_183{left:1106px;bottom:568px;letter-spacing:0.3px;}
#t1q_183{left:618px;bottom:545px;letter-spacing:0.11px;word-spacing:-0.16px;}
#t1r_183{left:618px;bottom:522px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1s_183{left:618px;bottom:498px;letter-spacing:0.18px;}
#t1t_183{left:665px;bottom:506px;letter-spacing:-0.01px;}
#t1u_183{left:618px;bottom:459px;letter-spacing:0.05px;word-spacing:0.41px;}
#t1v_183{left:618px;bottom:436px;letter-spacing:0.03px;word-spacing:0.27px;}
#t1w_183{left:618px;bottom:413px;letter-spacing:0.11px;word-spacing:-0.2px;}
#t1x_183{left:1139px;bottom:420px;letter-spacing:-0.01px;}
#t1y_183{left:1162px;bottom:413px;}
#t1z_183{left:618px;bottom:390px;letter-spacing:0.08px;word-spacing:0.22px;}
#t20_183{left:618px;bottom:366px;letter-spacing:0.13px;}
#t21_183{left:672px;bottom:374px;letter-spacing:-0.01px;}
#t22_183{left:695px;bottom:366px;letter-spacing:0.1px;word-spacing:0.08px;}
#t23_183{left:618px;bottom:343px;letter-spacing:0.09px;word-spacing:0.09px;}
#t24_183{left:618px;bottom:320px;letter-spacing:0.03px;word-spacing:0.16px;}
#t25_183{left:794px;bottom:327px;letter-spacing:-0.01px;}
#t26_183{left:818px;bottom:320px;letter-spacing:0.03px;word-spacing:0.16px;}
#t27_183{left:618px;bottom:297px;letter-spacing:0.09px;word-spacing:0.21px;}
#t28_183{left:618px;bottom:273px;letter-spacing:0.08px;word-spacing:0.34px;}
#t29_183{left:618px;bottom:250px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2a_183{left:618px;bottom:212px;letter-spacing:-0.11px;word-spacing:0.53px;}
#t2b_183{left:618px;bottom:188px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2c_183{left:618px;bottom:165px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t2d_183{left:838px;bottom:165px;letter-spacing:0.19px;}
#t2e_183{left:618px;bottom:141px;letter-spacing:0.17px;word-spacing:-1.21px;}
#t2f_183{left:763px;bottom:141px;letter-spacing:0.12px;word-spacing:-0.08px;}
#t2g_183{left:618px;bottom:118px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2h_183{left:618px;bottom:95px;letter-spacing:0.18px;word-spacing:0.02px;}
#t2i_183{left:618px;bottom:72px;letter-spacing:0.02px;word-spacing:-0.93px;}
#t2j_183{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_183{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_183{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_183{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_183{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_183{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_183{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_183{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_183{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s8_183{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s9_183{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts183" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg183Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg183" style="-webkit-user-select: none;"><object width="1210" height="935" data="183/183.svg" type="image/svg+xml" id="pdf183" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_183" class="t s0_183">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_183" class="t s1_183">© </span>
<span id="t3_183" class="t s0_183">(NCCN </span>
<span id="t4_183" class="t s1_183">© </span>
<span id="t5_183" class="t s0_183">), All rights reserved. NCCN Guidelines </span>
<span id="t6_183" class="t s1_183">® </span>
<span id="t7_183" class="t s0_183">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_183" class="t s2_183">NCCN Guidelines Version 4.2024 </span>
<span id="t9_183" class="t s2_183">Head and Neck Cancers </span>
<span id="ta_183" class="t s3_183">MS-42 </span>
<span id="tb_183" class="t s4_183">III JUPITER-02 trial. </span>
<span id="tc_183" class="t s5_183">553 </span>
<span id="td_183" class="t s4_183">Patients from China, Taiwan, and Singapore (N = </span>
<span id="te_183" class="t s4_183">289) were randomized to receive toripalimab or a placebo. PFS (HR, </span>
<span id="tf_183" class="t s4_183">0.52; 95% CI, 0.37–0.73) and OS (HR, 0.63; 95% CI, 0.45–0.89) were </span>
<span id="tg_183" class="t s4_183">both significantly greater in the toripalimab arm (median PFS 21.4 </span>
<span id="th_183" class="t s4_183">months, median OS not reached) compared to the placebo arm (median </span>
<span id="ti_183" class="t s4_183">PFS 8.2 months, median OS 33.7 months). Adverse events leading to </span>
<span id="tj_183" class="t s4_183">discontinuation of toripalimab or placebo, immune-related adverse </span>
<span id="tk_183" class="t s4_183">events, and grade 3 or greater immune-related adverse events were </span>
<span id="tl_183" class="t s4_183">more frequently reported in the toripalimab arm, although overall </span>
<span id="tm_183" class="t s4_183">incidence of adverse events, grade 3 or greater adverse events, and </span>
<span id="tn_183" class="t s4_183">fatal adverse events did not significantly differ between the two study </span>
<span id="to_183" class="t s4_183">arms. In addition, toripalimab monotherapy for recurrent or metastatic </span>
<span id="tp_183" class="t s4_183">NPC previously treated with chemotherapy is supported by a </span>
<span id="tq_183" class="t s4_183">nonrandomized phase II study from China (N = 190), showing an overall </span>
<span id="tr_183" class="t s4_183">response rate (ORR) of 20.5%, median DOR 12.8 months, median PFS </span>
<span id="ts_183" class="t s4_183">1.9 months, and median OS 17.4 months. </span>
<span id="tt_183" class="t s5_183">554 </span>
<span id="tu_183" class="t s4_183">Toripalimab-tpzi is therefore </span>
<span id="tv_183" class="t s4_183">a preferred option in the NCCN Guidelines for recurrent or metastatic </span>
<span id="tw_183" class="t s4_183">NPC, for disease progression on or after platinum-containing therapy. </span>
<span id="tx_183" class="t s4_183">The anti-programmed cell death protein 1 (PD-1) antibodies </span>
<span id="ty_183" class="t s4_183">camrelizumab and tislelizumab administered in combination with GC </span>
<span id="tz_183" class="t s4_183">have also been evaluated in randomized phase III trials from China, </span>
<span id="t10_183" class="t s5_183">555,556 </span>
<span id="t11_183" class="t s4_183">but these agents are not currently available in the United States. Due to </span>
<span id="t12_183" class="t s4_183">the limited availability of toripalimab and other formally tested agents, </span>
<span id="t13_183" class="t s4_183">practitioners have by necessity paired GC with other established anti- </span>
<span id="t14_183" class="t s4_183">PD-1 antibodies (eg, pembrolizumab, nivolumab) based on extrapolation. </span>
<span id="t15_183" class="t s4_183">The anti-PD-1 antibodies pembrolizumab and nivolumab have been </span>
<span id="t16_183" class="t s4_183">independently evaluated as monotherapy for previously treated, </span>
<span id="t17_183" class="t s4_183">recurrent or metastatic NPC in nonrandomized trials. Pembrolizumab in </span>
<span id="t18_183" class="t s4_183">patients with PD-L1–positive recurrent or metastatic NPC was assessed </span>
<span id="t19_183" class="t s4_183">in the nonrandomized multi-institutional phase IB KEYNOTE-028 trial (</span><span id="t1a_183" class="t s6_183">N </span>
<span id="t1b_183" class="t s4_183">= 27). </span>
<span id="t1c_183" class="t s5_183">557 </span>
<span id="t1d_183" class="t s4_183">All but two of the patients had previously received systemic </span>
<span id="t1e_183" class="t s4_183">therapy for their recurrent or metastatic disease. The objective response </span>
<span id="t1f_183" class="t s4_183">rate (partial response only, since no patients had a complete response) </span>
<span id="t1g_183" class="t s4_183">was 26%, with a median duration of response of 17.1 months. The OS </span>
<span id="t1h_183" class="t s4_183">rate at 6 and 12 months was 85% and 63%, respectively, with PFS rates </span>
<span id="t1i_183" class="t s4_183">of 39% and 34%, respectively. Approximately 30% of patients </span>
<span id="t1j_183" class="t s4_183">experienced a grade 3–5 drug-related adverse event. The panel </span>
<span id="t1k_183" class="t s4_183">recommends pembrolizumab for patients with previously treated PD-L1– </span>
<span id="t1l_183" class="t s4_183">positive recurrent or metastatic NPC, but this is a category 2B option </span>
<span id="t1m_183" class="t s4_183">based on panel consensus. Pembrolizumab is also an option for patients </span>
<span id="t1n_183" class="t s4_183">with previously treated tumor mutational burden-high (TMB-H; </span><span id="t1o_183" class="t s7_183">≥</span><span id="t1p_183" class="t s4_183">10 </span>
<span id="t1q_183" class="t s4_183">mut/Mb) disease, based on results from the phase II KEYNOTE-158 trial, </span>
<span id="t1r_183" class="t s4_183">although there were no patients with nasopharyngeal cancer in this </span>
<span id="t1s_183" class="t s4_183">study. </span>
<span id="t1t_183" class="t s5_183">558 </span>
<span id="t1u_183" class="t s4_183">Nivolumab as treatment for recurrent or metastatic NPC has been </span>
<span id="t1v_183" class="t s4_183">evaluated in phase I/II trials. In the CheckMate 358 trial, nivolumab had </span>
<span id="t1w_183" class="t s4_183">an ORR of 20.8% and a disease control rate of 45.8% in 24 patients. </span>
<span id="t1x_183" class="t s5_183">559 </span>
<span id="t1y_183" class="t s4_183">A </span>
<span id="t1z_183" class="t s4_183">Japanese study showed a more modest ORR of 16.7% and DCR of </span>
<span id="t20_183" class="t s4_183">41.7%. </span>
<span id="t21_183" class="t s5_183">560 </span>
<span id="t22_183" class="t s4_183">In an NCI sponsored trial, 44 patients with previously treated </span>
<span id="t23_183" class="t s4_183">recurrent or metastatic NPC (&gt;80% non-keratinizing disease) were </span>
<span id="t24_183" class="t s4_183">treated with nivolumab. </span>
<span id="t25_183" class="t s5_183">561 </span>
<span id="t26_183" class="t s4_183">The ORR was 20.5%, 1-year OS was 59%, </span>
<span id="t27_183" class="t s4_183">and 1-year PFS was 19.3%. Based on the results of these trials, </span>
<span id="t28_183" class="t s4_183">nivolumab is a category 2B treatment option for patients with previously </span>
<span id="t29_183" class="t s4_183">treated, recurrent or metastatic non-keratinizing NPC. </span>
<span id="t2a_183" class="t s8_183">Radiation Therapy Fractionation </span>
<span id="t2b_183" class="t s4_183">Radiation dose-fractionation schedules may vary slightly depending on </span>
<span id="t2c_183" class="t s4_183">institutional preference (see </span><span id="t2d_183" class="t s6_183">Cancer of the Nasopharynx: Principles of </span>
<span id="t2e_183" class="t s6_183">Radiation Therapy </span><span id="t2f_183" class="t s4_183">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t2g_183" class="t s4_183">Radiation doses of approximately 70 Gy given in standard fractions of </span>
<span id="t2h_183" class="t s4_183">approximately 2.0 Gy/fraction are recommended for control of the gross </span>
<span id="t2i_183" class="t s4_183">primary tumor and involved lymph nodes; one specific alternative schedule </span>
<span id="t2j_183" class="t s9_183">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
